Clinical trial
Evaluation of Galcanezumab in the Prevention of Episodic Migraine- the EVOLVE-1 Study (EVOLVE-1)
Evaluation of Galcanezumab in the Prevention of Episodic Migraine- the EVOLVE-1 Study (EVOLVE-1)
The main purpose of this study is to evaluate the efficacy of the study drug known as galcanezumab in participants with episodic migraine.
Study Type: Interventional (Clinical Trial)
Actual Enrollment: 862 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Episodic Migraine - the EVOLVE-1 Study
Actual Study Start Date: November 30, 2015
Actual Primary Completion Date: March 22, 2017
Actual Study Completion Date: August 9, 2018
Arms:
- Experimental: Galcanezumab 120mg
- Experimental: Galcanezumab 240mg
- Placebo Comparator: Placebo
| Category | Value |
|---|---|
| Study type(s) | Interventional |
| Expected enrolment | 862 |
| Actual Study start date | 30 November 2015 |
| Actual Study Completion Date | 09 August 2018 |